Concepts of healthy diet as expressed by primary health care workers in the national capital of Brazil

As mudanças alimentares na sociedade ocidental apontam para a importância de uma ação específica no campo da saúde individual e coletiva e colocam os profissionais sanitaristas como indivíduos estratégicos na promoção da alimentação saudável. O presente estudo tem o propósito de conhecer as concepções desses profissionais sobre a alimentação saudável, com base na técnica metodológica da pesquisa-ação aplicada em centros de saúde do Distrito Federal. Os resultados mostram que existe um aparente dualismo entre os conceitos envolvidos nesse tema, um que versa sobre a idealização alimentar e outro que situa o espaço da realidade concreta dos indivíduos. Ou seja, há um conceito sobre a alimentação para a saúde fundamentado na literatura científica e outro que se apóia neste, mas distingue-se no espaço interno do cotidiano. Neste último, os atores sociais fazem correspondências entre um saber e outro e trazem à tona os hábitos alimentares conjugados ao estilo de vida, mas, em ambas as concepções, a tendência é transcender o caráter biológico implícito na construção do conceito e apoiar-se nas condições sócio-culturais que as moldam e são moldadas no plano concreto da realidade.Dietary changes in Western society highlight the need for individual and collective health providers to use their strategic positions to actively promote healthy eating habits. Using the research-action methodology in various clinics in the Federal District of Brazil, the present study aimed to identify what these professionals consider a healthy diet. The results indicate an apparent conceptual dichotomy: on the one hand, an idealized version of eating for good health based on the scientific literature; on the other, a concept derived from the ideal, but based on people’s day-to-day reality. In their pursuit of the latter concept, people in social situations make connections between various pieces of information, and what emerges are the eating habits most closely associated with a particular lifestyle. However, both concepts tend to transcend the implicit biological character of the conceptual constructs and to find support in the sociocultural conditions that shape them and which in turn are shaped at the concrete level of reality

Effect of Low Molecular Weight Heparins (LMWHs) on antiphospholipid Antibodies (aPL)-mediated inhibition of endometrial angiogenesis

Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by vascular thrombosis and/or pregnancy morbidity in the presence of circulating antiphospholipid antibodies (aPL). Different pathogenic mechanisms for aPL-mediated pregnancy failure have been proposed. In particular a direct effect of aPL on both maternal and fetal side of the placental tissue has been reported, since their reactivity with \u3b22-glycoprotein I (\u3b22GPI) makes them adhere to trophoblast and human endometrial endothelial cell (HEEC) membranes. \u3b22GPI can be recognized by aPL that, once bound, interfere with both trophoblast functions and with the HEEC differentiation.APS patients can be successfully treated with Low Molecular Weight Heparin (LMWH). Recent reports suggest that LMWH acts through mechanisms alternative to its well known anticoagulant effect, because of its ability to bind \u3b22GPI. In our previous studies, we showed that LMWH is able to reduce the aPL binding to trophoblasts and restore cell invasiveness and differentiation. So far, however, no study has described its effects on endometrial angiogenesis.The aim of our research was to evaluate whether two LMWHs, tinzaparin and enoxaparin, have an effect on the aPL-inhibited endometrial angiogenesis. This prompted us to investigate: (i) in vitro HEEC angiogenesis through a Matrigel assay; (ii) VEGF secretion by ELISA; (iii) matrix metalloproteinase-2 (MMP-2) activity by gelatin zymography; (iv) Nuclear Factor-\u3baB (NF-\u3baB) DNA binding activity by colorimetric assay; (v) STAT-3 activation by a sandwich-ELISA kit. Furthermore, using an in vivo murine model we investigated the LMWHs effects on angiogenesis.We demonstrated that the addition of LMWHs prevents aPL-inhibited HEEC angiogenesis, both in vitro and in vivo, and is able to restore the aPL inhibited NF-\u3baB and/or STAT-3 activity, the VEGF secretion and the MMPs activity.The demonstration of a beneficial role for LMWHs on the aPL-inhibited HEEC angiogenesis might provide additional mechanisms whereby this treatment protects early pregnancy in AP

Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study

Background: Treatment of non–clear cell renal cell carcinoma (RCC) remains controversial despite several recent prospective studies of targeted therapies (TT). Often Vascular Endothelial growth Factor (VEGF) and Mammalian Target of Rapamycin (mTOR) inhibitors are used, extrapolating the data from use of these agents in clear cell RCC. Methods: We performed a retrospective data analysis within the Renal Cross Channel Group to determine metastatic chromophobe RCC (mChRCC) outcomes in the TT era. The end-points were overall response, overall survival (OS) and time to treatment failure (TTF). The two latter were estimated using the Kaplan–Meier method. Results: 91 mChRCC patients from 26 centres were included. Median follow-up from the date of first metastasis was 6.1 years (range: 0–13.9). Median OS was 37.9 months (95% confidence interval [CI]: 21.4–46.8) from the diagnosis of metastatic disease. Among the 61 patients who received TT, 50 (82%) were treated with anti-angiogenic (AA) and 11 with mTOR inhibitors. Median TTF and OS in patients receiving a first line of AA was 8.7 months (95% CI: 5.2–10.9) and 22.9 months (95% CI: 17.8–49.2) versus 1.9 months (95% CI: 1.0–6.0) and 3.2 months (95% CI: 2.3–not evaluable) with mTOR inhibitors, respectively. A stratified log-rank test was used to compare AA and mTOR inhibitors TT, while controlling the effect of the International Metastatic RCC Database Consortium risk group and no significant difference between AA and mTOR inhibitors was observed for TTF (p = 0.26) or for OS (p = 0.55). Conclusion: We report the largest retrospective cohort of patients with mChRCC treated with TT and no significant difference between AA and mTOR inhibitors was observed for TTF and OS